All In Biotech

Drug Trial Radar · NCT07801625

Investigating Nasal and Ocular Immune Response to Conjunctival Allergen Exposure

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Dr. Anne EllisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 3, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this pilot study is to develop an eye allergen challenge model, called a conjunctival allergen challenge (CAC), using timothy grass as the allergen. This model will allow for a more consistent approach to studying allergic rhinoconjunctivitis (allergy of the eye and nose) and help us better understand the connections between the eye and the nose. The two main questions asked in this study are: 1. How can allergic symptoms be safely and accurately produced in a research setting? 2. What are the underlying connections between the eye and the nose, and how do they drive allergic rhinoconjunctivitis? This study will recruit both timothy grass-allergic participants with a history of eye and nose symptoms and non-allergic participants. Allergic participants will: * Be challenged with timothy grass extract diluted in sterile saline using the CAC model, which involves administering the allergen directly to the eye in a manner similar to applying eye drops. * Have nasal fluid and tear samples collected at various timepoints up to 6 hours after CAC exposure. * Complete ocular and nasal symptom questionnaires and assessments by a eye care professional. * Visit the study site 3 separate times: 1. Screening visit (Visit 1): to determine eligibility for the study. 2. CAC visit (Visit 2): to receive allergen exposure, complete symptom questionnaires, and provide study samples. 3. Follow-up (Visit 3): to complete a final symptom questionnaire (24 hours after allergen exposure). Non-allergic participants will: * Be challenged with timothy grass extract diluted in sterile saline using the CAC model, administered directly to the eye similarly to eye drops. * Have nasal fluid and tear samples collected at various timepoints up to 6 hours after CAC exposure. * Complete ocular and nasal symptom questionnaires and assessments by a eye care professional. * Visit the study site 3 separate times: 1. Screening visit (Visit 1): to determine eligibility for the study. 2. CAC visit (Visit 2): to receive allergen exposure, complete symptom questionnaires, and provide study samples. 3. Follow-up (Visit 3): to complete a final symptom questionnaire (24 hours after allergen exposure) and receive another CAC and nasal sponge sample for allergen-tracking purposes. This study will compare the nasal and ocular symptoms and allergic markers collected from tear and nasal fluid samples between allergic and non-allergic participants at baseline and at several timepoints after CAC exposure. It will also measure the concentration of allergen in the nasal sponge samples of non-allergic participants at the follow-up visit to assess how the allergen moves from the eye to the nose.

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

  • Standardized Allergen Extract, Timothy Grass (Phleum pratense)Drug

    Timothy grass-allergic participants will be exposed to diluted Timothy grass allergen using the CAC model.

  • Standardized Allergen Extract, Timothy Grass (Phleum pratense)Drug

    Non-allergic participants will be exposed to diluted Timothy grass allergen using the CAC model.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Ocular Symptom Score (TOSS)Time frame: Pre-CAC up to 24 hours post-CAC.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kingston Health Sciences Centre - Kingston General Hospital

    Kingston, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.